-
1
-
-
0023266532
-
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
-
The CONSENSUS Trial Study Group
-
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
-
(1987)
N Engl J Med
, vol.316
, pp. 1429-1435
-
-
-
2
-
-
0032912752
-
Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I
-
Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20: 136-9.
-
(1999)
Eur Heart J
, vol.20
, pp. 136-139
-
-
Swedberg, K.1
Kjekshus, J.2
Snapinn, S.3
-
3
-
-
0036067860
-
Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease
-
Bennet JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung 2002; 31: 262-70.
-
(2002)
Heart Lung
, vol.31
, pp. 262-270
-
-
Bennet, J.A.1
Riegel, B.2
Bittner, V.3
Nichols, J.4
-
4
-
-
0026785561
-
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
-
The SOLVD investigators
-
The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
-
(1992)
N Engl J Med
, vol.327
, pp. 685-691
-
-
-
5
-
-
0037716744
-
Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study
-
Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843-8.
-
(2003)
Lancet
, vol.361
, pp. 1843-1848
-
-
Jong, P.1
Yusuf, S.2
Rousseau, M.F.3
Ahn, S.A.4
Bangdiwala, S.I.5
-
6
-
-
0038649984
-
Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials
-
Vermes E, Tardif J-C, Bourassa MG, Racine N, Levesque S, White M. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-31.
-
(2003)
Circulation
, vol.107
, pp. 2926-2931
-
-
Vermes, E.1
Tardif, J.-C.2
Bourassa, M.G.3
Racine, N.4
Levesque, S.5
White, M.6
-
7
-
-
0037432313
-
Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure. Insight From the Studies Of Left Ventricular Dysfunction (SOLVD)
-
Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J-C. Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure. Insight From the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-6.
-
(2003)
Circulation
, vol.107
, pp. 1291-1296
-
-
Vermes, E.1
Ducharme, A.2
Bourassa, M.G.3
Lessard, M.4
White, M.5
Tardif, J.-C.6
-
8
-
-
0026786643
-
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators
-
Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
-
(1992)
N Engl J Med
, vol.327
, pp. 669-677
-
-
Pfeffer, M.A.1
Braunwald, E.2
Moye, L.A.3
Basta, L.4
Brown, E.J.5
Cuddy, T.E.6
-
9
-
-
20844451359
-
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction The Survival And Ventricular Enlargement (SAVE) Study
-
Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction The Survival And Ventricular Enlargement (SAVE) Study. Circulation 2004; 110: 3667-73.
-
(2004)
Circulation
, vol.110
, pp. 3667-3673
-
-
Tokmakova, M.P.1
Skali, H.2
Kenchaiah, S.3
Braunwald, E.4
Rouleau, J.L.5
Packer, M.6
-
10
-
-
9044239676
-
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
-
The Trandolapril Cardiac Evaluation (TRACE) Study Group
-
The Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
-
(1995)
N Engl J Med
, vol.333
, pp. 1670-1676
-
-
-
11
-
-
0033519923
-
Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction
-
for the TRACE Study Group
-
Torp-Pedersen C, Køber L, for the TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 1999; 354: 9-12.
-
(1999)
Lancet
, vol.354
, pp. 9-12
-
-
Torp-Pedersen, C.1
Køber, L.2
-
12
-
-
0027423378
-
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
-
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators
-
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
-
(1993)
Lancet
, vol.342
, pp. 821-828
-
-
-
13
-
-
0030995759
-
on behalf of the AIREX Study Investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study
-
Hall AS, Murray GD, Ball SG, on behalf of the AIREX Study Investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-7.
-
(1997)
Lancet
, vol.349
, pp. 1493-1497
-
-
Hall, A.S.1
Murray, G.D.2
Ball, S.G.3
-
14
-
-
0037336098
-
Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: The CATS randomized trial
-
Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24: 412-20.
-
(2003)
Eur Heart J
, vol.24
, pp. 412-420
-
-
Hillege, H.L.1
van Gilst, W.H.2
van Veldhuisen, D.J.3
Navis, G.4
Grobbee, D.E.5
de Graeff, P.A.6
-
15
-
-
0035968623
-
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
-
PROGRESS Collaborative Group
-
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
-
(2001)
Lancet
, vol.358
, pp. 1033-1041
-
-
-
16
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
-
The Heart Outcome Prevention Evaluation Study Investigators
-
The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
-
(2000)
N Engl J Med
, vol.342
, pp. 145-153
-
-
-
17
-
-
0035936402
-
Blood-pressure reduction and cardiovascular risk in HOPE study
-
for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators
-
Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J, for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130-1.
-
(2001)
Lancet
, vol.358
, pp. 2130-2131
-
-
Sleight, P.1
Yusuf, S.2
Pogue, J.3
Tsuyuki, R.4
Diaz, R.5
Probstfield, J.6
-
18
-
-
0035916235
-
Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE)
-
for the SECURE Investigators
-
Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, et al., for the SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-25.
-
(2001)
Circulation
, vol.103
, pp. 919-925
-
-
Lonn, E.M.1
Yusuf, S.2
Dzavik, V.3
Doris, C.I.4
Yi, Q.5
Smith, S.6
-
19
-
-
2942518221
-
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. A substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial
-
Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan B, Tanser P, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. A substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 2004; 43: 2200-6.
-
(2004)
J Am Coll Cardiol
, vol.43
, pp. 2200-2206
-
-
Lonn, E.1
Shaikholeslami, R.2
Yi, Q.3
Bosch, J.4
Sullivan, B.5
Tanser, P.6
-
20
-
-
0025770138
-
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
-
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
-
(1991)
N Engl J Med
, vol.325
, pp. 303-310
-
-
Cohn, J.N.1
Johnson, G.2
Ziesche, S.3
Cobb, F.4
Francis, G.5
Tristani, F.6
-
21
-
-
4544371157
-
on behalf of the HOPE investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction
-
Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S, on behalf of the HOPE investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation 2004; 110: 1413-7.
-
(2004)
Circulation
, vol.110
, pp. 1413-1417
-
-
Teo, K.K.1
Mitchell, L.B.2
Pogue, J.3
Bosch, J.4
Dagenais, G.5
Yusuf, S.6
-
22
-
-
0034700790
-
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
-
HOPE Study Investigators
-
HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
-
(2000)
Lancet
, vol.355
, pp. 253-259
-
-
-
23
-
-
0018764335
-
Diabetes and cardiovascular disease. The Framingham study
-
Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-8.
-
(1979)
JAMA
, vol.241
, pp. 2035-2038
-
-
Kannel, W.B.1
McGee, D.L.2
-
24
-
-
0037092995
-
Diabetes and atherosclerosis. Epidemiology, pathophysiology and management
-
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management JAMA 2002; 108: 2570-81.
-
(2002)
JAMA
, vol.108
, pp. 2570-2581
-
-
Beckman, J.A.1
Creager, M.A.2
Libby, P.3
-
25
-
-
0141615827
-
Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: Part I
-
Creager MA, Luscher T, Cosentino F, Beckman JA. Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-32.
-
(2003)
Circulation
, vol.108
, pp. 1527-1532
-
-
Creager, M.A.1
Luscher, T.2
Cosentino, F.3
Beckman, J.A.4
-
26
-
-
0042330455
-
-
EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial the EUROPA study, Lancet 2003; 362: 782-8
-
EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
-
-
-
-
27
-
-
17144368928
-
on behalf of the EUROPA investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: Results from the PERSUADE substudy
-
Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML, on behalf of the EUROPA investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369-78.
-
(2005)
Eur Heart J
, vol.26
, pp. 1369-1378
-
-
Daly, C.A.1
Fox, K.M.2
Remme, W.J.3
Bertrand, M.E.4
Ferrari, R.5
Simoons, M.L.6
-
28
-
-
0344373794
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
-
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
-
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-97.
-
(2002)
JAMA
, vol.288
, pp. 2981-2997
-
-
-
29
-
-
19644400972
-
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
-
The PEACE Trial Investigators
-
The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
-
(2004)
N Engl J Med
, vol.351
, pp. 2058-2068
-
-
-
30
-
-
0026323498
-
Cause-specific mortality in a population-based study of diabetes
-
Moss SE, Klein R, Klein BEK. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991; 81: 1158-62.
-
(1991)
Am J Public Health
, vol.81
, pp. 1158-1162
-
-
Moss, S.E.1
Klein, R.2
Klein, B.E.K.3
-
31
-
-
0029962963
-
on behalf of WHO Multinational Study Group. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes
-
Wang SL, Head J, Stevens L, Fuller JH, on behalf of WHO Multinational Study Group. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes. Diabetes Care 1996; 19: 305-12.
-
(1996)
Diabetes Care
, vol.19
, pp. 305-312
-
-
Wang, S.L.1
Head, J.2
Stevens, L.3
Fuller, J.H.4
-
32
-
-
0026530073
-
Prognostic significance of microalbuminuria in insulin dependent diabetes mellitus: A twenty-three year follow-up study
-
Messent JWC, Elliot TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic significance of microalbuminuria in insulin dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992; 41: 836-9.
-
(1992)
Kidney Int
, vol.41
, pp. 836-839
-
-
Messent, J.W.C.1
Elliot, T.G.2
Hill, R.D.3
Jarrett, R.J.4
Keen, H.5
Viberti, G.C.6
-
33
-
-
0027517659
-
The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
-
for the Collaborative Study Group
-
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. N Engl J Med 1993; 329: 1456-62.
-
(1993)
N Engl J Med
, vol.329
, pp. 1456-1462
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Bain, R.P.3
Rohde, R.D.4
-
34
-
-
0028860451
-
on behalf of the North American Microalbuminemia Study Group. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria
-
Laffel LMB, McGill JB, Gans DJ, on behalf of the North American Microalbuminemia Study Group. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995; 99: 497-504.
-
(1995)
Am J Med
, vol.99
, pp. 497-504
-
-
Laffel, L.M.B.1
McGill, J.B.2
Gans, D.J.3
-
35
-
-
0030908772
-
Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
-
The EUCLID Study Group
-
The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92.
-
(1997)
Lancet
, vol.349
, pp. 1787-1792
-
-
-
36
-
-
34248520946
-
-
Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. http://www.acc.org/clinical/ statements.htm
-
Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. http://www.acc.org/clinical/ statements.htm
-
-
-
-
37
-
-
0037221669
-
Heart failure and the aging population: An increasing burden in the 21st century?
-
Stewart S, MacIntyre K, Capewell S, McMurray JJV. Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003; 89: 49-53.
-
(2003)
Heart
, vol.89
, pp. 49-53
-
-
Stewart, S.1
MacIntyre, K.2
Capewell, S.3
McMurray, J.J.V.4
-
39
-
-
0036023644
-
Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases
-
Dell'Italia LJ, Husain A. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol 2002; 17: 374-9.
-
(2002)
Curr Opin Cardiol
, vol.17
, pp. 374-379
-
-
Dell'Italia, L.J.1
Husain, A.2
-
40
-
-
0034612118
-
on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II
-
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
-
(2000)
Lancet
, vol.355
, pp. 1582-1587
-
-
Pitt, B.1
Poole-Wilson, P.A.2
Segal, R.3
Martinez, F.A.4
Dickstein, K.5
Camm, A.J.6
-
41
-
-
0035818884
-
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
-
for the Valsartan Heart Failure Trial Investigators
-
Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
-
(2001)
N Engl J Med
, vol.345
, pp. 1667-1675
-
-
Cohn, J.N.1
Tognoni, G.2
-
42
-
-
17844369714
-
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
-
Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-57.
-
(2005)
Am Heart J
, vol.149
, pp. 548-557
-
-
Maggioni, A.P.1
Latini, R.2
Carson, P.E.3
Singh, S.N.4
Barlera, S.5
Glazer, R.6
-
43
-
-
0038376029
-
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
-
Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-204.
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 2197-2204
-
-
Kumagai, K.1
Nakashima, H.2
Urata, H.3
Gondo, N.4
Arakawa, K.5
Saku, K.6
-
44
-
-
0035923479
-
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure
-
Li D, Shinagawa K, Li P, Leung TK, Cardin S, Wang Z, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-14.
-
(2001)
Circulation
, vol.104
, pp. 2608-2614
-
-
Li, D.1
Shinagawa, K.2
Li, P.3
Leung, T.K.4
Cardin, S.5
Wang, Z.6
-
45
-
-
18144365472
-
Effect of valsartan on quality of life when added to usual therapy for heart failure: Results from the Valsartan Heart Failure Trial
-
Majani G, Giardini A, Opasich C, Glazer R, Hester A, Tognoni G, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. J Card Fail 2005; 11: 253-9.
-
(2005)
J Card Fail
, vol.11
, pp. 253-259
-
-
Majani, G.1
Giardini, A.2
Opasich, C.3
Glazer, R.4
Hester, A.5
Tognoni, G.6
-
46
-
-
0042410539
-
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme
-
for the CHARM Investigators and Committees
-
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JVJ, Michelson EL, et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
-
(2003)
Lancet
, vol.362
, pp. 759-766
-
-
Pfeffer, M.A.1
Swedberg, K.2
Granger, C.B.3
Held, P.4
McMurray, J.V.J.5
Michelson, E.L.6
-
47
-
-
0041408234
-
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM Preserved Trial
-
for the CHARM Investigators and Committees
-
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003; 362: 777-81.
-
(2003)
Lancet
, vol.362
, pp. 777-781
-
-
Yusuf, S.1
Pfeffer, M.A.2
Swedberg, K.3
Granger, C.B.4
Held, P.5
McMurray, J.J.V.6
-
48
-
-
0041408235
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: The CHARM-Added trial
-
for the CHARM Investigators and Committees
-
McMurray JJV, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
-
(2003)
Lancet
, vol.362
, pp. 767-771
-
-
McMurray, J.J.V.1
Östergren, J.2
Swedberg, K.3
Granger, C.B.4
Held, P.5
Michelson, E.L.6
-
49
-
-
0041909380
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting-enzyme inhibitors: The CHARM-Alternative trial
-
for the CHARM Investigators and Committees
-
Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.
-
(2003)
Lancet
, vol.362
, pp. 772-776
-
-
Granger, C.B.1
McMurray, J.J.V.2
Yusuf, S.3
Held, P.4
Michelson, E.L.5
Olofsson, B.6
-
50
-
-
7544249402
-
Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction
-
for the CHARM Investigators and Committees
-
Young JB, Dunlap ME, Pfeffer M, Probstfield JL, Cohen-Solal A, Dietz R, et al. for the CHARM Investigators and Committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Circulation 2004; 110: 2618-26.
-
(2004)
Circulation
, vol.110
, pp. 2618-2626
-
-
Young, J.B.1
Dunlap, M.E.2
Pfeffer, M.3
Probstfield, J.L.4
Cohen-Solal, A.5
Dietz, R.6
-
51
-
-
7544246246
-
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
-
O'Meara E, Solomon S, McMurray JJV, Pfeffer M, Yusuf S, Michelson E, et al. Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2004; 25: 1920-6.
-
(2004)
Eur Heart J
, vol.25
, pp. 1920-1926
-
-
O'Meara, E.1
Solomon, S.2
McMurray, J.J.V.3
Pfeffer, M.4
Yusuf, S.5
Michelson, E.6
-
52
-
-
0242490542
-
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
-
for the Valsartan in Acute Myocardial Infarction Trial Investigators
-
Pfeffer M, McMurray JJV, Velazquez EJ, Rouleau J-L, Køber L, Maggioni AP, et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
-
(2003)
N Engl J Med
, vol.349
, pp. 1893-1906
-
-
Pfeffer, M.1
McMurray, J.J.V.2
Velazquez, E.J.3
Rouleau, J.-L.4
Køber, L.5
Maggioni, A.P.6
-
53
-
-
0037160968
-
a randomised trial against atenolol
-
for LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study LIFE
-
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. for LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
-
(2002)
Lancet
, vol.359
, pp. 995-1003
-
-
Dahlof, B.1
Devereux, R.B.2
Kjeldsen, S.E.3
Julius, S.4
Beevers, G.5
de Faire, U.6
-
54
-
-
0037174372
-
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint reduction in hypertension (LIFE) substudy
-
for LIFE Study Group
-
Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. for LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint reduction in hypertension (LIFE) substudy. JAMA 2002; 288: 1491-8.
-
(2002)
JAMA
, vol.288
, pp. 1491-1498
-
-
Kjeldsen, S.E.1
Dahlof, B.2
Devereux, R.B.3
Julius, S.4
Aurup, P.5
Edelman, J.6
-
55
-
-
0035922444
-
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
-
for Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
-
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, et al. for Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
-
(2001)
N Engl J Med
, vol.345
, pp. 870-878
-
-
Parving, H.H.1
Lehnert, H.2
Brochner-Mortensen, J.3
Gomis, R.4
Andersen, S.5
Arner, P.6
-
56
-
-
7444237666
-
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
-
for the Diabetics Exposed to Telmisartan and Enalapril Study Group
-
Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. for the Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 352: 1952-61.
-
(2004)
N Engl J Med
, vol.352
, pp. 1952-1961
-
-
Barnett, A.H.1
Bain, S.C.2
Bouter, P.3
Karlberg, B.4
Madsbad, S.5
Jervell, J.6
-
57
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
for the RENAAL Study Investigators
-
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
-
(2001)
N Engl J Med
, vol.345
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
de Zeeuw, D.3
Keane, W.F.4
Mitch, W.E.5
Parving, H.H.6
-
58
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes
-
for the Collaborative Group
-
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. for the Collaborative Group. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
-
(2001)
N Engl J Med
, vol.345
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
Berl, T.4
Pohl, M.A.5
Lewis, J.B.6
-
59
-
-
18744380400
-
The ONTARGET/TRANSCEND Trial Programme: Baseline data
-
Sleight P. The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetol 2005; 42: S50-6.
-
(2005)
Acta Diabetol
, vol.42
-
-
Sleight, P.1
-
60
-
-
0041332950
-
The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme
-
Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme. J Hypertens Suppl 2003; 21: S37-46.
-
(2003)
J Hypertens Suppl
, vol.21
-
-
Weber, M.1
-
61
-
-
0023195849
-
Monocrotaline-induced cardiopulmonary injury in rats: Modification by thiol and nonthiol ACE inhibitors
-
Molteni A, Ward W, Ts'ao C, Solliday N. Monocrotaline-induced cardiopulmonary injury in rats: modification by thiol and nonthiol ACE inhibitors. Clin Exp Hypertens A 1987; 9: 381-5.
-
(1987)
Clin Exp Hypertens A
, vol.9
, pp. 381-385
-
-
Molteni, A.1
Ward, W.2
Ts'ao, C.3
Solliday, N.4
-
62
-
-
0036794826
-
Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species
-
Cominacini L, Pasini AF, Garbin U, Evangelista S, Crea AEG, Tagliacozzi D, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15: 891-5.
-
(2002)
Am J Hypertens
, vol.15
, pp. 891-895
-
-
Cominacini, L.1
Pasini, A.F.2
Garbin, U.3
Evangelista, S.4
Crea, A.E.G.5
Tagliacozzi, D.6
-
63
-
-
0033847306
-
Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure
-
Buikema H, Monnink SHJ, Tio RA, Crijns HJGM, de Zeeuw D, van Gilst WH. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharm 2000; 130: 1999-2007.
-
(2000)
Br J Pharm
, vol.130
, pp. 1999-2007
-
-
Buikema, H.1
Monnink, S.H.J.2
Tio, R.A.3
Crijns, H.J.G.M.4
de Zeeuw, D.5
van Gilst, W.H.6
-
64
-
-
17944397753
-
Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension
-
Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: K1-6.
-
(2004)
Am Heart J
, vol.148
-
-
Napoli, C.1
Sica, V.2
de Nigris, F.3
Pignalosa, O.4
Condorelli, M.5
Ignarro, L.J.6
-
65
-
-
0028609776
-
Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis
-
Friedrich SP, Lorell BH, Rousseau MF, Hayashida W, Hess OM, Douglas PS, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994; 90: 2761-71.
-
(1994)
Circulation
, vol.90
, pp. 2761-2771
-
-
Friedrich, S.P.1
Lorell, B.H.2
Rousseau, M.F.3
Hayashida, W.4
Hess, O.M.5
Douglas, P.S.6
-
66
-
-
0028030372
-
Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis
-
Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994; 90: 1410-22.
-
(1994)
Circulation
, vol.90
, pp. 1410-1422
-
-
Weinberg, E.O.1
Schoen, F.J.2
George, D.3
Kagaya, Y.4
Douglas, P.S.5
Litwin, S.E.6
-
67
-
-
0035997523
-
Pathophysiologic and therapeutic importance of tissue ACE
-
16: 149-60
-
Dzau VJ, Bernstein K, Clermajer D, Cohen J, Dahlof B, Deanfield J, et al. Pathophysiologic and therapeutic importance of tissue ACE: A Consensus Report Cardiov Drug Ther 2002; 16: 149-60.
-
A Consensus Report Cardiov Drug Ther 2002
-
-
Dzau, V.J.1
Bernstein, K.2
Clermajer, D.3
Cohen, J.4
Dahlof, B.5
Deanfield, J.6
-
68
-
-
18744382492
-
Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors
-
Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005; 11(14): 1795-804.
-
(2005)
Curr Pharm Des
, vol.11
, Issue.14
, pp. 1795-1804
-
-
Cheng, H.F.1
Harris, R.C.2
-
69
-
-
16244416574
-
The reno-protective effect of the dual blockade of the renin angiotensin system (RAS)
-
Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005; 11(10): 1291-300.
-
(2005)
Curr Pharm Des
, vol.11
, Issue.10
, pp. 1291-1300
-
-
Luno, J.1
Praga, M.2
de Vinuesa, S.G.3
-
70
-
-
32944454689
-
Perspectives of new antihypertensive drugs
-
Wang JG. Perspectives of new antihypertensive drugs. Curr Pharm Des 2005; 11(25): 3273.
-
(2005)
Curr Pharm Des
, vol.11
, Issue.25
, pp. 3273
-
-
Wang, J.G.1
|